Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial

By sjmartinez • August 1, 2024

Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav. 2024 Jul 31. doi: 10.1007/s10461-024-04451-7. Epub ahead of print. PMID: 39083151.

Tags: Adherence, CASI, HIV prevention, Infectious Diseases, Maraviroc, PrEP, Publications, Tenofovir

HIV Drug Resistance to Dolutegravir Among Adults Investigated for Antiretroviral Treatment Failure in Malawi: A 2023 National Cross-Sectional Survey

Kalata NL, Bello G, Pals S, Kabaghe AN, Mkungudza J, Bighignoli B, Panja L, Bilaal W, Kusakale G, Chitenje M, Luhanga M, Zeh C, Kampira[...]

The Relationship Between HIV Preexposure Prophylaxis Use and Laboratory-Confirmed Bacterial Sexually Transmitted Infection Positivity Among a Diverse, Multi-City Cohort of Sexually Active Sexual and Gender Minorities in the United States

Yonko EA, Tian J, Aminzadeh K, Qian Y, Noori G, Plankey M, Friedman MR, Palella FJ, Jones DL, Wingood G, Sharma A, Dionne JA, Edmonds[...]

Description of T-Cell and Monocyte Populations in the Circulation of People with HIV Prior to AIDS-NHL Diagnosis

Martínez LE, Comin-Anduix B, Güemes-Aragon M, Ibarrondo J, Detels R, Mimiaga MJ, Epeldegui M. Description of T-Cell and Monocyte Populations in the Circulation of People[...]